ĀÜĄņĀŅĀ×

Mr. Margus currently serves as Co-Founder and Chief Executive Officer of Cerevance, a private, clinical-stage drug development company focused on pursuing novel targets for brain diseases. In addition to Cerevance, Mr. Margus has co-founded several biotechnology companies including Perlegen Sciences, a tools and diagnostics company focused on using genetic variation to improve clinical decision making, and Envoy Therapeutics, focused on advancing a pipeline of compounds that acted on proteins selectively expressed in the disrupted circuitry of brain diseases. Envoy Therapeutics was acquired by Takeda Pharmaceuticals in 2012. Mr. Margus has been a member of numerous government advisory committees as well as corporate and nonprofit boards. He currently serves on the boards of Arvinas Inc., Global Genes, a non-profit organization that advocates on behalf of all rare diseases, and the non-profit A-T Childrenā€™s Project. Additionally, he serves as the Co-Chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the NIH. Mr. Margus received his M.B.A. from Harvard Business School.